AI-powered trial screening helps community oncology practices identify eligible patients locally, widening access beyond ...
The recent FDA approval of iberdomide (Zenbexus) represents more than the approval of a single new drug for ...
The first patient has been dosed in MODeFIRe-1 (NCT07745361), a phase 2 study evaluating MRT-2359 in combination with ...
The benefit of daraxonrasib in PDAC may be overstated in RASolute 302 due to informative censoring. The RASolute 302 trial (NCT06625320) in pancreatic cancer has received a lot of attention. The study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results